Last edition
News about "Sanjeev Jain"
Akums Drugs and Pharmaceuticals Reports 35.4 Percent EBITDA Growth in Q1 FY27
Akums Drugs and Pharmaceuticals starts FY27 on a strong note, reporting robust revenue, EBITDA and PAT growth as its CDMO business continues to drive performance.
Sanjeev Jain | 11/08/2026 | By News Bureau
Akums Receives First UK MHRA Approval for Rivaroxaban
Rivaroxaban is an oral anticoagulant prescribed for the prevention and treatment of thromboembolic disorders, including Non-Valvular Atrial Fibrillation (NVAF), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE) and clinically relevant cardiovascular risk reduction.
Sanjeev Jain | 10/02/2026 | By News Bureau | 197
Akums Secures EU GMP Approval for Two Haridwar Facilities
The approvals follow successful EU-GMP audits of Akums’ two Haridwar manufacturing facilities, with the drug regulator renewing certification for plant I and granting fresh approval to plant II after assessing operations, quality systems, documentation and compliance with EU GMP standards.
Sanjeev Jain | 23/01/2026 | By News Bureau | 285
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy